Pharma BD Deal Intelligence

Amgen Inc. / BioVex Group, Inc.

2011 · Acquisition/Merger · $1.0B · Complete

Amgen completed acquisition of BioVex on March 4, 2011 for $425M upfront plus up to $575M in regulatory and sales milestones. Lead asset OncoVEX (later Imlygic/T-VEC) was a Phase 3 oncolytic immunotherapy for melanoma; FDA-approved 2015.

Did it work? Outcome assessment

Assessment window: 5yr post-close.

Key facts

• Announced Mar 04, 2011
• Closed Mar 04, 2011
• Deal value $1.0B
• Deal type Acquisition/Merger
• Therapeutic area Metastatic melanoma; head and neck cancer
• Indications Metastatic melanoma; head and neck cancer
• Key assets OncoVEX GM-CSF (talimogene laherparepvec, T-VEC)
• Mechanism Oncolytic HSV-1 virus encoding GM-CSF

← Browse all deals  ·  How we score deals